Today, Commerce Bank decides to keep it stake in Teva Pharmaceutical Industries Ltd. (TEVA) to the level of $1,953,000

Today, Commerce Bank decides to keep it stake in Teva Pharmaceutical Industries Ltd. (TEVA) to the level of $1,953,000
Commerce Bank decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,438 shares of the company’s stock after selling 2,864 shares during the period. Commerce Bank’s holdings in Teva Pharmaceutical Industries were worth $1,953,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of TEVA. Barrow Hanley Mewhinney & Strauss LLC increased its position in Teva Pharmaceutical Industries by 143.7% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,700,812 shares of the company’s stock worth $1,140,263,000 after buying an additional 13,385,352 shares during the last quarter. Capital Research Global Investors increased its position in Teva Pharmaceutical Industries by 49.6% in the second quarter. Capital Research Global Investors now owns 17,265,800 shares of the company’s stock worth $867,261,000 after buying an additional 5,722,500 shares during the last quarter. Franklin Resources Inc. increased its position in Teva Pharmaceutical Industries by 11.9% in the second quarter. Franklin Resources Inc. now owns 41,211,549 shares of the company’s stock worth $2,070,095,000 after buying an additional 4,389,590 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 92.8% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 7,466,908 shares of the company’s stock worth $375,062,000 after buying an additional 3,594,209 shares during the last quarter. Finally, Schroder Investment Management Group increased its position in Teva Pharmaceutical Industries by 45.0% in the second quarter. Schroder Investment Management Group now owns 7,654,733 shares of the company’s stock worth $384,498,000 after buying an additional 2,375,340 shares during the last quarter. Institutional investors own 63.16% of the company’s stock.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded up 0.26% during midday trading on Friday, hitting $38.21. 2,320,788 shares of the stock traded hands. The company has a market cap of $38.78 billion, a price-to-earnings ratio of 22.23 and a beta of 0.73. Teva Pharmaceutical Industries Ltd. has a 52-week low of $37.12 and a 52-week high of $66.55. The stock has a 50-day moving average of $41.87 and a 200-day moving average of $49.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. The company earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the company posted $1.35 EPS. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post $5.14 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Thursday, December 1st. Teva Pharmaceutical Industries’s dividend payout ratio is currently 50.58%.

TEVA has been the subject of a number of analyst reports. RBC Capital Markets set a $71.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Sunday, September 11th. Deutsche Bank AG set a $68.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Saturday, October 15th. Credit Suisse Group AG reaffirmed a “neutral” rating and set a $51.63 target price (down previously from $59.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 25th. Oppenheimer Holdings Inc. set a $66.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Monday, September 12th. Finally, Bank of America Corp. downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $48.00 price target for the company. in a research report on Monday, November 7th. Thirteen research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $60.00.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment